top of page
Nelson Advisors > European Healthcare Technology Investment Banking


Blackbird Ventures Fund VI: Analysis of Capital Deployment, AI Realignment and Scale Economics in ANZ Venture Capital
The successful closure of Blackbird Ventures' Fund VI at A$1.05 billion represents a critical structural milestone in the maturation of the Australia and New Zealand (ANZ) private capital markets. Marginally exceeding its A$1.035 billion predecessor from 2022, the vehicle stands as the largest single venture capital fund raised in the region's history. Beyond its absolute capital magnitude, the composition of the fund’s Limited Partner (LP) base signals a structural shift in
Nelson Advisors
3 days ago


Epic Systems’ AI Expansion and the Structural Transformation of the HealthTech Startup Ecosystem
The rapid native expansion of Epic Systems into generative artificial intelligence and agentic workflow automation represents a structural pivot in the digital health sector. Epic controls 43.7% of the US acute care electronic health record (EHR) market, serving over 3,700 hospitals, 45,000 clinics and maintaining active medical records for more than 325 million patients. The healthcare technology startup landscape, which attracted over $1.4 billion in venture capital investm
Nelson Advisors
Aug 20


Australian HealthTech Market: 2026 State of Play & Outlook to 2028
Australia's healthtech sector is exhibiting structural, not cyclical, growth in 2026. The digital health market, valued at USD $8.9 Billion in 2025, is forecast to reach USD $31.1 Billion by 2034 at a CAGR of 14.92%, underpinned by AI-led diagnostics, remote patient monitoring, aged care digitisation and a Federal Government committing billions to national digital health infrastructure.
Nelson Advisors
Jun 2


H2 2026 represents a pivotal transition for European Ambient Clinical AI
The European healthcare technology and clinical artificial intelligence sectors have transitioned into an era of disciplined industrialisation. The speculative fragmentation and "growth-at-all-costs" investment thesis that characterized the zero-interest-rate policy era have been replaced by a rigorous focus on unit economics, real-world clinical evidence, and deep workflow integration. As the market approaches the second half of 2026, venture capital deployment in clinical A
Nelson Advisors
May 30
bottom of page